THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Monday, March 23, 2026

COMPOUND WATCH

Retatrutide (LY3437943) [Phase 3] — Triple GIP/GLP-1/glucagon agonist TRANSCEND-T2D-1 topline: A1C ↓ 2.0% | Weight ↓ 16.8% / 36.6 lbs at 40 weeks in T2D patients. No weight loss plateau at end of treatment. That last detail is the headline — tirzepatide plateaus around 36 weeks in comparable populations.

The correct comparison: in T2D populations, tirzepatide hits roughly 9–10% weight loss — retatrutide just nearly doubled that. But the more apples-to-apples number is in non-T2D obesity: SURMOUNT-1 showed tirzepatide at 21.4–22.5% at 10–15mg over 72 weeks, with ~63% of patients achieving ≥20% body weight loss. Retatrutide's TRIUMPH-4 obesity data came in at 28.7% at highest dose over 68 weeks. That 6–7 point gap — in a comparable population — is the actual competitive ceiling being set. Full TRANSCEND-T2D-1 data at ADA Scientific Sessions in June. Seven additional Phase 3 trials ongoing; two actively recruiting now (NCT07232719, NCT07357415).

AE profile during dose escalation: nausea 16.4–26.5%, diarrhea 18.7–26.3%, vomiting 15.7–17.6% — roughly comparable to tirzepatide's ramp. One new signal: dysesthesia (abnormal skin sensation) in 2.3–4.5% vs. 0% placebo. This rate is not seen with GLP-1 mono or dual agonists. Mechanism unclear. Watch the June full-data presentation for dose-response detail on this.

Semaglutide (Wegovy HD, 7.2mg injectable pen) [Phase 3] — FDA approved higher-dose injectable pen through accelerated review. Distinct from the oral Wegovy pill — this is a subcutaneous injection at a higher dose. Post-approval confirmatory studies required; safety profile at 7.2mg is being collected in real-world patients right now, not in a controlled trial. If you're on 2.4mg and plateauing, this is the next step in the branded stack. No compounder equivalent at this dose exists yet.

Orforglipron [Phase 3] — Lilly's oral non-peptide GLP-1 RA. FDA decision pushed to April 10. LLY stock dropped 3.8% on the delay; LLY is now -13% YTD. Novo's oral Wegovy launched earlier this month and holds first-mover advantage. Lilly has $1.5B in pre-launch inventory. The delay is FDA backlog, not an application problem. April 10 is a binary catalyst — if approved, watch for the pricing announcement within 24 hours. If the price lands above ~$400/month, compounding demand for oral GLP-1 alternatives stays intact.

BPC-157 [Animal] — Zero published human RCTs. The first Phase 2 human trial (NCT07437547, acute hamstring muscle strain) began recruiting February 2026 and is currently active. This is the only registered human RCT for BPC-157 in existence. Small trial, early phase, results 12–18 months out — but it moves BPC-157 from [Animal] toward [Phase 2] on the evidence ladder. If results are positive, compounder demand spikes and gray-market pricing follows.

ATR-258 (Atrogi) [Phase 1→Human Efficacy] — Oral β2-adrenergic receptor modulator targeting skeletal muscle preservation during fat loss. First subjects dosed in an 8-week human trial at University of Copenhagen (announced March 18). Builds on a June 2025 Cell publication and Phase 1 data in 69 subjects (safe and well-tolerated). If you're running tirzepatide or semaglutide and GLP-1-induced muscle loss is your primary concern, this is the compound to track. Not a peptide, not available — but the first oral muscle-preserving metabolic drug entering human efficacy testing is directly relevant to anyone stacking for body composition.

CBL-514 + GLP-1R combination (Caliway) [Phase 2/3] — CBL-514 is a first-in-class injectable small molecule that induces adipocyte apoptosis (targeted fat cell elimination). 10 completed clinical trials, 544 subjects, all efficacy/safety endpoints met. FDA IND submission for Phase 2 in weight management combined with GLP-1RA is complete. Health Canada approved Phase 3 SUPREME-01. Preclinical combination data selected for oral presentation at ECO 2026 (Istanbul, May 12–15). If you're stacking compounds for body composition, this is the most advanced non-GLP-1 adjunct in the pipeline.

VENDOR SIGNAL

No new Finnrick rating changes, failed HPLC results, or Janoshik data surfaced March 21–23. No new FDA warning letters or raids on named research peptide vendors confirmed for this window.

What we do have: A California Trim Clinic PR piece explicitly targeting Silicon Valley biohackers using "gray-market Chinese peptides." No pricing disclosed. No independent testing data cited. This is marketing dressed as safety reporting — it contributes zero new information. But the framing signals that US telehealth clinics are now actively competing against the gray-market channel in the biohacking demographic. Expect more of this as the 503A/503B channel tries to pull users away from QSC/SRY/GYC.

Baseline risk reminder: Community estimates — not a published study, flag accordingly — suggest 15–20% of supplier COAs show discrepancies when independently verified by third-party HPLC. The most recent hard data point: GenoGenix (prior week), bacterial endotoxin in a compounded GLP-1 product, 3 ER visits. That was a licensed compounder, not a gray-market Chinese vendor. The risk is not exclusively in the gray market.

No compounder pricing updates today for Empower, Olympia, or Marek. Checked — no fresh data available. If you're deciding whether to reorder this week, current pricing at those three is unchanged from last week's data.

Action: No vendor rating changes to report. Check finnrick.com before your next order. If your BPC-157 source has no independent HPLC verification, the Phase 2 trial news above is a reasonable moment to reconsider your sourcing tier.

[COA Only] — No specific vendor being rated COA Only today; label applies to any vendor providing only their own certificate without independent verification. If that's your current source, that's your risk level. [Flagged] — GenoGenix (prior week, bacterial endotoxin, compounded GLP-1, 3 ER visits)

TRIAL TRACKER

NCT07437547 — BPC-157, Phase 2, Acute Hamstring Muscle Strain [Phase 2 | Recruiting | Started Feb 2, 2026] The only registered human RCT for BPC-157 in existence. If you're injecting BPC-157 today, this trial is the entire scientific foundation for whether that decision will ever be validated. Watch for interim signals in late 2026.

NCT07232719 / NCT07357415 — Retatrutide Phase 3, Obesity/Overweight [Phase 3 | Recruiting] Two active Phase 3 retatrutide trials recruiting now, on top of this week's TRANSCEND-T2D-1 topline win. The no-plateau weight loss signal at 40 weeks in T2D — combined with 28.7% in TRIUMPH-4 obesity — makes retatrutide the compound to track if you're on tirzepatide and watching the next-gen landscape.

NCT07227948 — Semaglutide for Cocaine Use Disorder, Phase 2 [Phase 2 | Recruiting | Started Jan 2026] GLP-1 receptor agonism is now in Phase 2 for addiction. The dopamine/reward pathway mechanism is the same one driving the "GLP-1 quiets food noise" anecdotes. If this reads out positive, the GLP-1 indication list expands significantly — and so does the demand curve for compounded semaglutide.

THE ODDS

Inflation above 3% in 2026: 97% probability ($197K volume) — The number that matters most for your monthly peptide budget. Empower, Olympia, and Marek pricing is tied to API costs, labor, and overhead — all inflation-sensitive. The gray-market channel has its own inflation vector: tariffs on Chinese goods. Your $300/month peptide spend is going up, not down.

Tariff dividend by March 31: 1% probability ($145K volume) — Near-zero. More relevant: the existing 25% tariff regime on Chinese goods translates to roughly a 15–30% cost increase on gray-market BPC-157, TB-500, and CJC-1295 at the point of US entry. No new customs seizure data today, but the structural risk is priced into every order from a Chinese vendor.

Recession by end of 2026: 36% probability ($742K volume) — Below the threshold where gray-market demand historically spikes over compounding pharmacy demand. That threshold — roughly 40–45% — is a rule of thumb based on prior demand cycles in discretionary health spending, not a published model; treat it as a heuristic. At 36%, most readers are still in the "pay for quality" mindset. If this number drifts above 40%, the calculus shifts: more people move down-market to unverified vendors, and contamination risk in the community increases. Watch the number, not just the level.

No Fed rate cuts in 2026: 38% probability ($2.4M volume) — Elevated rates keep out-of-pocket healthcare spending tight. The $449/month Zepbound Employer Connect price and $900+ brand Ozempic are both more painful in this environment. This is the macro backdrop pushing people toward compounders and gray-market — and it's not resolving in 2026.

The macro environment: persistent inflation, elevated rates, tariff risk on Chinese supply. Every vector pushes your peptide costs up. The only deflationary force is India's generic semaglutide flood — and that's not a US sourcing option yet.

SIGNAL VS. NOISE

SIGNAL: Retatrutide TRANSCEND-T2D-1 Phase 3 — 16.8% weight loss in T2D, no plateau at 40 weeks; 28.7% in TRIUMPH-4 obesity vs. tirzepatide's 21–22%. The correct comparison is obesity vs. obesity, not T2D vs. T2D. Both data points now exist. Retatrutide outperforms tirzepatide in both populations. Doesn't change your sourcing decision today — it's investigational — but it sets the competitive ceiling everything else gets benchmarked against for the next 3 years.

SIGNAL: India semaglutide patent expiry — Rs 325/week (Glenmark GLIPIQ) to Rs 4,200/month (Dr. Reddy's Obeda), confirmed March 20. The generic flood materialized faster and cheaper than projected. Five companies launched same day. The Rs 325/week to Rs 4,200/month spread (~$3.90–$50/month USD) reflects vial vs. pen format, dose, and brand positioning — not quality differences. Sun Pharma's Noveltreat runs Rs 900–2,000/week; Zydus launched three brands at ~Rs 2,200/month; Natco's multi-dose vials at Rs 1,290/month. The 10x price spread within India on day one tells you this market is still finding its floor. Not a US sourcing option — customs seizure risk is high for any import attempt. But this is the global pricing anchor event that makes the $900/month Ozempic price politically untenable within 12–18 months.

SIGNAL: ATR-258 first human efficacy dosing (University of Copenhagen). GLP-1-induced muscle loss is the #1 concern for anyone running tirzepatide or semaglutide long-term. An oral muscle-preserving compound entering human efficacy testing is directly actionable context — not for sourcing today, but for understanding what the next-gen stack looks like.

SIGNAL: BPC-157 Phase 2 human trial actively recruiting (NCT07437547). First registered human RCT for BPC-157. Moves the compound from [Animal] toward [Phase 2] on the evidence ladder. Watch enrollment pace — if it fills quickly, that's institutional interest signal.

NOISE: California Trim Clinic PR piece targeting "gray-market Chinese peptides." Marketing dressed as safety reporting. No independent testing data. No specific vendor named. No new regulatory action cited. The underlying safety concern is real — but this piece contributes zero new information. Ignore the framing.

NOISE: Nanexa PharmaShell quarterly semaglutide — rat PK data + human modeling only. Interesting concept. Smoother Cmax/Cmin profile than weekly Wegovy could reduce GI side effects. But rat pharmacokinetics and human modeling are not human data. The only human validation in the pipeline is 2025 Phase 1 liraglutide data. File it, don't act on it. This is a 3–5 year story if it works.

NOISE: SEAD1 peptide (Northwestern, Neuron, March 19) — single injection correcting cognitive deficits in schizophrenia mouse model. Real paper, real DOI (10.1016/j.neuron.2026.02.004), CSF biomarker identified in 100+ human patients — that's a meaningful translational step. But it's a mouse model. Team is optimizing for clinical trials in 16p11.2 duplication syndrome. For the nootropic peptide audience: file it, don't source it. [Animal] evidence only.

NOISE: Brenipatide Phase 2 for asthma [Phase 2] — Novel GIP/GLP-1 application for airway inflammation, single site (Kelowna, BC), excludes current GLP-1 users. Not actionable for this audience today.

REGULATORY RADAR

RFK/FDA peptide reclassification: Still no formal rule. As of March 23, 2026, no Federal Register notice, no HHS announcement, no FDA rulemaking has moved Category 2 peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu) to Category 1. Enforcement discretion is in place — but enforcement discretion is not a rule. It can be reversed without notice and provides no legal protection to compounders filling these compounds. If your 503A compounder is banking on this discretion, understand the legal exposure they're carrying on your behalf.

No new FDA warning letters or raids confirmed for March 21–23. Most recent enforcement action remains the 30 warning letters to telehealth companies over compounded GLP-1 products (reported March 19), including the GenoGenix bacterial endotoxin case.

Wegovy HD (7.2mg injectable pen) approved via accelerated pathway. Post-approval confirmatory studies required — the safety profile at 7.2mg is being collected in real-world patients right now. That's the informed consent context if you or your prescriber are considering this dose.

Orforglipron April 10 FDA decision: Binary catalyst. If approved and priced above ~$400/month, compounding demand for oral GLP-1 alternatives remains intact. If priced below $400/month, the calculus shifts. Watch for the pricing announcement concurrent with approval — that number is the signal, not the approval itself.

India CDSCO issued influencer advertising warning for GLP-1 lifestyle weight-loss promotion on day one of patent expiry. Delhi High Court demanded DCGI explanations on approval process gaps. The world's largest generic semaglutide market is already generating regulatory friction.

WHAT TO WATCH

April 10 — Orforglipron FDA decision. Binary. If approved: the pricing announcement within 24 hours is the signal. Above ~$400/month = compounding demand intact. Below = watch for compounder capacity announcements within the week. If denied or delayed again: compounded oral GLP-1 demand stays elevated.

ADA Scientific Sessions, June 2026 — Full TRANSCEND-T2D-1 data. The topline is strong. The full dataset will show the dose-response curve, dysesthesia signal detail, and cardiovascular markers. This is when the retatrutide story either solidifies or develops complications. If the dysesthesia signal (2.3–4.5% vs. 0% placebo) expands in the full dataset, that's a flag worth tracking before any gray-market retatrutide sourcing conversation starts.

ECO 2026, Istanbul, May 12–15 — CBL-514 + GLP-1R combination oral presentation. First public presentation of the combination adipocyte-apoptosis + GLP-1 preclinical data. If the combination signal is strong, this is the next compound the stacking community will be watching.

Ongoing — India generic semaglutide pricing floor. Track whether any US-based gray-market import channels emerge. Currently no legal US sourcing pathway. Customs seizure risk is high. But Rs 325/week will attract attention — watch r/Semaglutide for import discussion threads.

Ongoing — BPC-157 Phase 2 trial (NCT07437547) enrollment pace. If this trial fills quickly, it signals institutional interest. If it stalls, that's data too.

SCORECARD: We flagged March 20–24 as the India semaglutide patent expiry window (medium confidence). Confirmed and exceeded — patent expired March 20, five companies launched same day, pricing more aggressive than projected (Rs 325/week vs. expected ~75% discount from brand). ✓

The most important number in peptides this week isn't a price — it's the gap between 28.7% and 21.4%. That's retatrutide vs. tirzepatide in obesity populations. Everything in the GLP-1 space gets benchmarked against that gap from here.

Reply to this email with feedback — what do you want more of, what's missing, what's wrong.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $15/month. Manage your subscription.